<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>医药魔方Info | wechat-feeds</title><link>http://MzU2MTcxOTAwMw.favicon.privacyhide.com/favicon.ico</link><description>传递医药信息，分享资源数据！充电5分钟，吹牛2小时！</description><managingEditor> (hellodword)</managingEditor><pubDate>Thu, 22 Apr 2021 07:23:44 +0800</pubDate><image><url>http://MzU2MTcxOTAwMw.favicon.privacyhide.com/favicon.ico</url><title>医药魔方Info | wechat-feeds</title><link>http://MzU2MTcxOTAwMw.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>首个新型口服PI3K双重抑制剂申报上市并拟优先审评，石药集团4500万美元引进</title><link>https://mp.weixin.qq.com/s/6CgXGUOqWgIVDfTERE6A0Q</link><description></description><content:encoded><![CDATA[首个新型口服PI3K双重抑制剂申报上市并拟优先审评，石药集团4500万美元引进]]></content:encoded><pubDate>Wed, 21 Apr 2021 18:49:02 +0800</pubDate></item><item><title>直播预告| 2020中国医药市场回顾</title><link>https://mp.weixin.qq.com/s/riazdlg9d7pjEMGGo6o-Aw</link><description></description><content:encoded><![CDATA[直播预告| 2020中国医药市场回顾]]></content:encoded><pubDate>Wed, 21 Apr 2021 18:49:02 +0800</pubDate></item><item><title>恒瑞PD-1鼻咽癌适应症即将获批</title><link>https://mp.weixin.qq.com/s/kAciCWKqQ2jDxhghasocpA</link><description></description><content:encoded><![CDATA[恒瑞PD-1鼻咽癌适应症即将获批]]></content:encoded><pubDate>Wed, 21 Apr 2021 18:49:02 +0800</pubDate></item><item><title>恒瑞2款新药获批临床</title><link>https://mp.weixin.qq.com/s/uIvjI-lqWeABiEpEvMBhKQ</link><description></description><content:encoded><![CDATA[恒瑞2款新药获批临床]]></content:encoded><pubDate>Wed, 21 Apr 2021 18:49:02 +0800</pubDate></item><item><title>司美格鲁肽即将在华获批上市！</title><link>https://mp.weixin.qq.com/s/f3_sJA_vgPk3U_W8CpXPcw</link><description></description><content:encoded><![CDATA[司美格鲁肽即将在华获批上市！]]></content:encoded><pubDate>Tue, 20 Apr 2021 11:56:20 +0800</pubDate></item><item><title>first in class胃癌一线疗法获FDA突破性疗法，再鼎拥有大中华区开发权益</title><link>https://mp.weixin.qq.com/s/gnIz-EHVP5eGhbZ8mVKHPg</link><description></description><content:encoded><![CDATA[first in class胃癌一线疗法获FDA突破性疗法，再鼎拥有大中华区开发权益]]></content:encoded><pubDate>Tue, 20 Apr 2021 11:56:20 +0800</pubDate></item><item><title>恒瑞2020年财报：营收277亿，肿瘤药贡献55%，PD-1增3倍！净利润63.28亿，研发投入50亿</title><link>https://mp.weixin.qq.com/s/_JP8pPJMNW9YOuSLr0P_2Q</link><description></description><content:encoded><![CDATA[恒瑞2020年财报：营收277亿，肿瘤药贡献55%，PD-1增3倍！净利润63.28亿，研发投入50亿]]></content:encoded><pubDate>Mon, 19 Apr 2021 20:42:40 +0800</pubDate></item><item><title>首仿！海正药业「盐酸鲁拉西酮片」即将获批上市</title><link>https://mp.weixin.qq.com/s/IvvzyEmnFYvPKOyph_Qs2A</link><description></description><content:encoded><![CDATA[首仿！海正药业「盐酸鲁拉西酮片」即将获批上市]]></content:encoded><pubDate>Mon, 19 Apr 2021 20:42:40 +0800</pubDate></item><item><title>首款胃癌一线免疫疗法获FDA批准</title><link>https://mp.weixin.qq.com/s/hV1rWTh1N0L_AKgxcLoxwg</link><description></description><content:encoded><![CDATA[首款胃癌一线免疫疗法获FDA批准]]></content:encoded><pubDate>Sat, 17 Apr 2021 10:31:51 +0800</pubDate></item><item><title>Biogen富马酸二甲酯在华获批上市，2020年全球销售额38.41亿美元</title><link>https://mp.weixin.qq.com/s/czylPN1lcXccKVFw2JmCMA</link><description></description><content:encoded><![CDATA[Biogen富马酸二甲酯在华获批上市，2020年全球销售额38.41亿美元]]></content:encoded><pubDate>Fri, 16 Apr 2021 18:55:05 +0800</pubDate></item><item><title>首个STING激动剂获批临床</title><link>https://mp.weixin.qq.com/s/-Y4gZyoCxUuiMoZ71H3mEw</link><description></description><content:encoded><![CDATA[首个STING激动剂获批临床]]></content:encoded><pubDate>Fri, 16 Apr 2021 18:55:05 +0800</pubDate></item><item><title>一年又一年｜CSCO 指南照亮“人间四月天”——乳腺癌领域更新解读（上篇）</title><link>https://mp.weixin.qq.com/s/rHnCwnCzW9oWxcqV4Ih7Ig</link><description></description><content:encoded><![CDATA[一年又一年｜CSCO 指南照亮“人间四月天”——乳腺癌领域更新解读（上篇）]]></content:encoded><pubDate>Fri, 16 Apr 2021 18:55:05 +0800</pubDate></item><item><title>第五批国采60个品种开始报量（附竞争企业清单下载）</title><link>https://mp.weixin.qq.com/s/lU0p6Ix0ZsBn4UnXADKVkA</link><description></description><content:encoded><![CDATA[第五批国采60个品种开始报量（附竞争企业清单下载）]]></content:encoded><pubDate>Thu, 15 Apr 2021 15:29:59 +0800</pubDate></item><item><title>辉瑞第三代ALK抑制剂lorlatinib在华申报上市，治疗NSCLC</title><link>https://mp.weixin.qq.com/s/21IkOVxewVCRyTZ9JC40FA</link><description></description><content:encoded><![CDATA[辉瑞第三代ALK抑制剂lorlatinib在华申报上市，治疗NSCLC]]></content:encoded><pubDate>Thu, 15 Apr 2021 15:29:59 +0800</pubDate></item><item><title>强生中国区高管「杨炜」出任云顶新耀CSO</title><link>https://mp.weixin.qq.com/s/dPixepU8mM_n6rYMC9dqJA</link><description></description><content:encoded><![CDATA[强生中国区高管「杨炜」出任云顶新耀CSO]]></content:encoded><pubDate>Thu, 15 Apr 2021 15:29:59 +0800</pubDate></item><item><title>150亿美元！赛默飞拟收购PPD</title><link>https://mp.weixin.qq.com/s/4ht9yuidEqkWIMjmKm-Oxg</link><description></description><content:encoded><![CDATA[150亿美元！赛默飞拟收购PPD]]></content:encoded><pubDate>Thu, 15 Apr 2021 15:29:59 +0800</pubDate></item><item><title>新型口服疗法获FDA突破性疗法认定，治疗1型糖尿病</title><link>https://mp.weixin.qq.com/s/8Mio3dT5jdWR0khSvoHwtg</link><description></description><content:encoded><![CDATA[新型口服疗法获FDA突破性疗法认定，治疗1型糖尿病]]></content:encoded><pubDate>Thu, 15 Apr 2021 15:29:59 +0800</pubDate></item><item><title>PPT+视频回放 | 2021AACR新机会分析</title><link>https://mp.weixin.qq.com/s/sY9eIvTZIiMJpe9Io3hE2A</link><description></description><content:encoded><![CDATA[PPT+视频回放 | 2021AACR新机会分析]]></content:encoded><pubDate>Wed, 14 Apr 2021 17:31:12 +0800</pubDate></item><item><title>2021 AACR| 聚焦肿瘤耐药创新疗法！这家公司公布4个项目临床前数据</title><link>https://mp.weixin.qq.com/s/xnmsulkKD9eWi_B-u4yrkg</link><description></description><content:encoded><![CDATA[2021 AACR| 聚焦肿瘤耐药创新疗法！这家公司公布4个项目临床前数据]]></content:encoded><pubDate>Wed, 14 Apr 2021 17:31:12 +0800</pubDate></item><item><title>3月肺癌月报 | 振奋！国产三代EGFR-TKI登顶柳叶刀子刊；百济PD-1亮相JAMA Oncol，晚期NSCLC一线战鼓不休</title><link>https://mp.weixin.qq.com/s/E0er9gwlXG4YOMmbRCf_Ng</link><description></description><content:encoded><![CDATA[3月肺癌月报 | 振奋！国产三代EGFR-TKI登顶柳叶刀子刊；百济PD-1亮相JAMA Oncol，晚期NSCLC一线战鼓不休]]></content:encoded><pubDate>Wed, 14 Apr 2021 17:31:12 +0800</pubDate></item></channel></rss>